GEN

Improving CAR-T Cell Efficacy via New Manufacturing Process

At the 2024 annual meeting of the International Society for Cell & Gene Therapy (ISCT) in Vancouver, Canada, Hélio Tomás, PhD, senior research associate at the Instituto de Biologia Experimental e ...
BioPharma Dive

Building a robust in-process testing plan for cell therapy manufacturing success

Data integrity is key to the success of any cell therapy program. CDMOs can implement robust data management systems for ...
Business Wire

BrightPath Bio and Cellistic Announces Process Development and Manufacturing Collaboration for Phase 1 Clinical Trial of iPSC-derived BCMA CAR-iNKT cell

TOKYO & MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--BrightPath Bio (Tokyo Stock Exchange Growth 4594, “BrightPath”), a pioneer in iPS cell-derived Natural Killer T (“NKT”) cell therapy, and ...
Nasdaq

CD8 Technology Signs Letter of Intent for Tevogen Bio’s In-House Manufacturing Facility, Marking First Phase of Up to $50 Million Commitment

This press release contains certain forward-looking statements, including without limitation statements relating to: Tevogen’s plans for its research and manufacturing capabilities; Tevogen’s ability ...
Nasdaq

Tevogen Bio Holdings Inc. Announces Letter of Intent with CD8 Technology Services for Cell Therapy Manufacturing Facility

Tevogen Bio Holdings Inc. announced that CD8 Technology Services LLC has signed a letter of intent to design a facility that will support Tevogen’s cell therapy manufacturing efforts. CEO Ryan Saadi ...
EurekAlert!

Neutrophil extracellular traps license macrophage production of chemokines to facilitate CD8+ T cell infiltration in obstruction-induced renal fibrosis

NETs promote macrophage expression of T-cell chemokines and subsequently facilitate cytotoxic CD8+ T cell infiltration and granzyme B production, which drives kidney fibrosis in obstructive ...